Outcomes by time points of BSID assessments | Number of Trials | Sample Size | SMD (95% CI) | Heterogeneity Statistics |
---|---|---|---|---|
Zinc Alone vs. Placebo | Â | Â | Â | Â |
6 Months: | Â | Â | Â | Â |
MDI | 4 | 591 | -0.18 (−0.39 to 0.02)a | I2 = 37.4%, Χ2 = 4.79 |
PDI | 4 | 591 | 0.17 (−0.20 to 0.55) | I2 = 80.8%, Χ2 = 15.60 |
12 Months: | Â | Â | Â | Â |
MDI | 6 | 977 | -0.08 (−0.36 to 0.19) | I2 = 77.4%, Χ2 = 22.14 |
PDI | 6 | 977 | 0.30 (−0.24 to 0.83) | I2 = 94.00%, Χ2 = 80.23 |
Zinc with Iron vs. Iron | Â | Â | Â | Â |
6 Months: | Â | Â | Â | Â |
MDI | 2 | 359 | 0.09 (−0.11 to 0.30) | I2 = 0.00, Χ2 = 0.01 |
PDI | 2 | 359 | 0.07 (−0.14 to 0.28) | I2 = 0.00, Χ2 = 0.42 |
12 Months: | Â | Â | Â | Â |
MDI | 4 | 790 | -0.03 (−0.17 to 0.11) | I2 = 0.00, Χ2 = 1.02 |
PDI | 4 | 790 | 0.01 (−0.24 to 0.26) | I2 = 66.40, Χ2 = 8.94 |